Inflammation and cancer, Nature, vol.420, pp.860-867, 2002. ,
The double edge sword of fibrosis in cancer, Transl. Res, vol.209, pp.55-67, 2019. ,
, Cancers, vol.12, 1364.
The myofibroblast matrix: Implications for tissue repair and fibrosis, J. Pathol, vol.229, pp.298-309, 2013. ,
Perspective of Targeting Cancer-Associated Fibroblasts in Melanoma, J. Cancer, vol.6, pp.717-726, 2015. ,
The evolving relationship of wound healing and tumor stroma, JCI Insight, vol.3, 2018. ,
Blocking CXCR4 alleviates desmoplasia, increases T-lymphocyte infiltration, and improves immunotherapy in metastatic breast cancer, Proc. Natl. Acad. Sci, vol.116, pp.4558-4566, 2019. ,
, Fibroblast Heterogeneity and Immunosuppressive Environment in Human Breast Cancer. Cancer Cell, vol.33, pp.463-479, 2018.
Tumor-stromal crosstalk in pancreatic cancer and tissue fibrosis, Mol. Cancer, vol.18, 2019. ,
Lung cancer in patients with idiopathic pulmonary fibrosis, Eur. Respir. J, vol.17, pp.1216-1219, 2001. ,
Idiopathic Pulmonary Fibrosis and Lung Cancer: Mechanisms and Molecular Targets, Int. J. Mol. Sci, vol.20, 2019. ,
Why target the tumor stroma in melanoma?, J. Cell Commun. Signal, vol.12, pp.113-118, 2018. ,
A feed-forward mechanosignaling loop confers resistance to therapies targeting the MAPK pathway in BRAF-mutant melanoma, Cancer Res, 2020. ,
URL : https://hal.archives-ouvertes.fr/inserm-02889519
Roads to melanoma: Key pathways and emerging players in melanoma progression and oncogenic signaling, Biochim. Biophys. Acta, vol.1863, pp.770-784, 2016. ,
From melanocytes to melanomas, Nat. Rev. Cancer, vol.16, pp.345-358, 2016. ,
MC1R variants, melanoma and red hair color phenotype: A meta-analysis, Int. J. Cancer, vol.122, pp.2753-2760, 2008. ,
High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL, Cancer Res, vol.66, pp.9818-9828, 2006. ,
The Complexity of the ERK/MAP-Kinase Pathway and the Treatment of Melanoma Skin Cancer. Front, Cell Dev. Biol, 2016. ,
, Cancer Genome Atlas, N. Genomic Classification of Cutaneous Melanoma. Cell, vol.161, pp.1681-1696, 2015.
The Rac GTPase in Cancer: From Old Concepts to New Paradigms, Cancer Res, vol.77, pp.5445-5451, 2017. ,
Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma, Nat. Genet, vol.44, pp.1006-1014, 2012. ,
Mutational heterogeneity in cancer and the search for new cancer-associated genes, Nature, vol.499, pp.214-218, 2013. ,
, Epigenetics of malignant melanoma. Semin. Cancer Biol, vol.51, pp.80-88, 2018.
Improved survival with vemurafenib in melanoma with BRAF V600E mutation, N. Engl. J. Med, vol.364, pp.2507-2516, 2011. ,
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma, N. Engl. J. Med, vol.381, pp.626-636, 2019. ,
Pembrolizumab versus Ipilimumab in Advanced Melanoma, N. Engl. J. Med, vol.372, pp.2521-2532, 2015. ,
Immunotherapy of Melanoma: Facts and Hopes, Clin. Cancer Res, vol.25, pp.5191-5201, 2019. ,
Nivolumab plus ipilimumab in advanced melanoma, N. Engl. J. Med, vol.369, pp.122-133, 2013. ,
Targeted agents and immunotherapies: Optimizing outcomes in melanoma, Nat. Rev. Clin. Oncol, vol.14, pp.463-482, 2017. ,
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: Long-term survival and safety analysis of a phase 3 study, Ann. Oncol, vol.28, pp.1631-1639, 2017. ,
Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy, Cancer Discov, vol.4, pp.80-93, 2014. ,
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation, Nature, vol.468, pp.973-977, 2010. ,
Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance, Cell, vol.162, pp.1271-1285, 2015. ,
Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma, Nature, vol.508, pp.118-122, 2014. ,
In vivo switching of human melanoma cells between proliferative and invasive states, Cancer Res, vol.68, pp.650-656, 2008. ,
Human cutaneous melanomas lacking MITF and melanocyte differentiation antigens express a functional Axl receptor kinase, J. Investig. Dermatol, vol.131, pp.2448-2457, 2011. ,
Systematic classification of melanoma cells by phenotype-specific gene expression mapping, Pigment Cell Melanoma Res, vol.25, pp.343-353, 2012. ,
The immune microenvironment confers resistance to MAPK pathway inhibitors through macrophage-derived TNFalpha, Cancer Discov, vol.4, pp.1214-1229, 2014. ,
Inflammation-Induced Plasticity in Melanoma Therapy and Metastasis, Trends Immunol, vol.37, pp.364-374, 2016. ,
Translation reprogramming is an evolutionarily conserved driver of phenotypic plasticity and therapeutic resistance in melanoma, Genes Dev, vol.31, pp.18-33, 2017. ,
Phenotype plasticity as enabler of melanoma progression and therapy resistance, Nat. Rev. Cancer, vol.19, pp.377-391, 2019. ,
Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy, Cancer Cell, vol.29, pp.270-284, 2016. ,
Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K, Cancer Cell, vol.18, pp.683-695, 2010. ,
Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma, Cancer Discov, vol.3, pp.158-167, 2013. ,
Adaptive resistance of melanoma cells to RAF inhibition via reversible induction of a slowly dividing de-differentiated state, Mol. Syst. Biol, vol.13, p.905, 2017. ,
Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma, Nat. Commun, vol.5, 2014. ,
A proliferative melanoma cell phenotype is responsive to RAF/MEK inhibition independent of BRAF mutation status, Pigment Cell Melanoma Res, vol.24, pp.326-333, 2011. ,
Molecular Pathways: Maintaining MAPK Inhibitor Sensitivity by Targeting Nonmutational Tolerance, Clin. Cancer Res, vol.22, pp.5966-5970, 2016. ,
Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells, Cancer Cell, vol.23, pp.811-825, 2013. ,
A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations, Cell, vol.141, pp.69-80, 2010. ,
Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance, Nature, vol.546, pp.431-435, 2017. ,
Recurrent Tumor Cell-Intrinsic and -Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation, Cancer Discov, vol.7, pp.1248-1265, 2017. ,
Sustained activation of the Aryl hydrocarbon Receptor transcription factor promotes resistance to BRAF-inhibitors in melanoma, Nat. Commun, vol.9, p.4775, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-01972443
, Toward Minimal Residual Disease-Directed Therapy in Melanoma. Cell, vol.174, pp.843-855, 2018.
Multi-stage Differentiation Defines Melanoma Subtypes with Differential Vulnerability to Drug-Induced Iron-Dependent Oxidative Stress, Cancer Cell, vol.33, pp.890-904, 2018. ,
Single-cell analysis resolves the cell state transition and signaling dynamics associated with melanoma drug-induced resistance, Proc. Natl. Acad. Sci, vol.114, pp.13679-13684, 2017. ,
The myofibroblast in wound healing and fibrocontractive diseases, J. Pathol, vol.200, pp.500-503, 2003. ,
The myofibroblast: Paradigm for a mechanically active cell, J. Biomech, vol.43, pp.146-155, 2010. ,
Membrane and acto-myosin tension promote clustering of adhesion proteins, Proc. Natl. Acad. Sci, vol.101, pp.2229-2234, 2004. ,
Tumor immunotherapy targeting fibroblast activation protein, a product expressed in tumor-associated fibroblasts, Cancer Res, vol.65, pp.11156-11163, 2005. ,
Effect of protein kinase inhibitor H-7 on the contractility, integrity, and membrane anchorage of the microfilament system, Cell Motil. Cytoskelet, vol.29, pp.321-338, 1994. ,
Focal adhesions, contractility, and signaling, Annu. Rev. Cell Dev. Biol, vol.12, pp.463-518, 1996. ,
Linking actin dynamics and gene transcription to drive cellular motile functions, Nat. Rev. Mol. Cell Biol, vol.11, pp.353-365, 2010. ,
Control of cellular responses to mechanical cues through YAP/TAZ regulation, J. Biol. Chem, vol.294, pp.17693-17706, 2019. ,
YAP regulates cell mechanics by controlling focal adhesion assembly, Nat. Commun, 2017. ,
A Role of Myocardin Related Transcription Factor-A (MRTF-A) in Scleroderma Related Fibrosis, PLoS ONE, vol.10, 2015. ,
Myocardin-related transcription factor-A complexes activate type I collagen expression in lung fibroblasts, J. Biol. Chem, vol.286, pp.44116-44125, 2011. ,
Inhibition of myocardin-related transcription factor/serum response factor signaling decreases lung fibrosis and promotes mesenchymal cell apoptosis, Am. J. Pathol, vol.185, pp.969-986, 2015. ,
Myocardin-related transcription factor-a controls myofibroblast activation and fibrosis in response to myocardial infarction, Circ. Res, vol.107, pp.294-304, 2010. ,
A new lock-step mechanism of matrix remodelling based on subcellular contractile events, J. Cell. Sci, vol.123, pp.1751-1760, 2010. ,
TGF-beta signaling in fibrosis, Growth Factors, vol.29, pp.196-202, 2011. ,
Regulation of PDGF and its receptors in fibrotic diseases, Cytokine Growth Factor Rev, vol.15, pp.255-273, 2004. ,
Crosstalk between fibroblasts and inflammatory cells, Cardiovasc. Res, vol.102, pp.258-269, 2014. ,
Fibrotic extracellular matrix activates a profibrotic positive feedback loop, J. Clin. Investig, vol.124, pp.1622-1635, 2014. ,
Mechanosignaling through YAP and TAZ drives fibroblast activation and fibrosis, Am. J. Physiol. Lung Cell Mol. Physiol, vol.308, pp.344-357, 2015. ,
MicroRNA-21 preserves the fibrotic mechanical memory of mesenchymal stem cells, Nat. Mater, vol.16, pp.379-389, 2017. ,
Extracellular matrix as a driver of progressive fibrosis, J. Clin. Investig, vol.128, pp.45-53, 2018. ,
ROCK and JAK1 signaling cooperate to control actomyosin contractility in tumor cells and stroma, Cancer Cell, vol.20, pp.229-245, 2011. ,
ICAM-1 and VCAM-1 gene expression and cytokine production in human duodenal fibroblasts stimulated with lipopolysaccharide, IL-1 alpha and TNF-alpha, Clin. Exp. Immunol, vol.96, pp.437-443, 1994. ,
Novel roles for chemokines and fibroblasts in interstitial fibrosis, Kidney Int, vol.54, pp.2152-2159, 1998. ,
Myofibroblasts. I. Paracrine cells important in health and disease, Am. J. Physiol, vol.277, pp.1-9, 1999. ,
URL : https://hal.archives-ouvertes.fr/hal-01931267
Mesenchymal cells stimulate human intestinal intraepithelial lymphocytes, Gastroenterology, vol.113, pp.144-150, 1997. ,
A cytokine reborn? Endothelin-1 in pulmonary inflammation and fibrosis, Am. J. Respir. Cell Mol. Biol, vol.23, pp.7-10, 2000. ,
Potential role of endothelin-1 in pulmonary fibrosis: From the bench to the clinic, Am. J. Respir. Cell Mol. Biol, vol.42, pp.16-20, 2010. ,
Environment-mediated drug resistance: A major contributor to minimal residual disease, Nat. Rev. Cancer, vol.9, pp.665-674, 2009. ,
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion, Nature, vol.487, pp.500-504, 2012. ,
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors, Nature, vol.487, pp.505-509, 2012. ,
the aged microenvironment drives melanoma metastasis and therapy resistance, Nature, vol.532, pp.250-254, 2016. ,
BRAF Inhibition Generates a Host-Tumor Niche that Mediates Therapeutic Escape, J. Investig. Dermatol, vol.135, pp.3115-3124, 2015. ,
Intravital imaging reveals how BRAF inhibition generates drug-tolerant microenvironments with high integrin beta1/FAK signaling, Cancer Cell, vol.27, pp.574-588, 2015. ,
An adaptive signaling network in melanoma inflammatory niches confers tolerance to MAPK signaling inhibition, J. Exp. Med, vol.214, pp.1691-1710, 2017. ,
Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells, Oncogene, vol.35, pp.1225-1235, 2016. ,
The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells, Matrix Biol, vol.48, pp.66-77, 2015. ,
New Mechanisms of Resistance to MEK Inhibitors in Melanoma Revealed by Intravital Imaging, Cancer Res, vol.78, pp.542-557, 2018. ,
Collagen abundance controls melanoma phenotypes through lineage-specific microenvironment sensing, Oncogene, vol.37, pp.3166-3182, 2018. ,
Vemurafenib resistance increases melanoma invasiveness and modulates the tumor microenvironment by MMP-2 upregulation, Pharmacol. Res, vol.111, pp.523-533, 2016. ,
B-RAF regulation of Rnd3 participates in actin cytoskeletal and focal adhesion organization, Mol. Biol. Cell, vol.19, pp.498-508, 2008. ,
ROCK1 is a potential combinatorial drug target for BRAF mutant melanoma, Mol. Syst. Biol, vol.10, p.772, 2014. ,
Phosphoproteomic Analysis of Cell-Based Resistance to BRAF Inhibitor Therapy in Melanoma. Front, Oncol, vol.5, p.95, 2015. ,
JUN dependency in distinct early and late BRAF inhibition adaptation states of melanoma ,
Actin remodeling confers BRAF inhibitor resistance to melanoma cells through YAP/TAZ activation, EMBO J, vol.35, pp.462-478, 2016. ,
Rho-mediated signaling promotes BRAF inhibitor resistance in de-differentiated melanoma cells, Oncogene, vol.39, pp.1466-1483, 2020. ,
RAC1(P29S) Induces a Mesenchymal Phenotypic Switch via Serum Response Factor to Promote Melanoma Development and Therapy Resistance, Cancer Cell, vol.36, pp.68-83, 2019. ,
Myosin II Reactivation and Cytoskeletal Remodeling as a Hallmark and a Vulnerability in Melanoma Therapy Resistance, Cancer Cell, vol.37, pp.85-103, 2020. ,
Combination of MEK and SRC inhibition suppresses melanoma cell growth and invasion, Oncogene, vol.32, pp.86-96, 2013. ,
MEK inhibition affects STAT3 signaling and invasion in human melanoma cell lines, Oncogene, vol.33, pp.1850-1861, 2014. ,
Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation, Nature, vol.490, pp.412-416, 2012. ,
Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure, EMBO Mol. Med, vol.9, pp.1011-1029, 2017. ,
MAPK pathway inhibition enhances the efficacy of an anti-endothelin B receptor drug conjugate by inducing target expression in melanoma, Mol. Cancer Ther, vol.13, pp.1599-1610, 2014. ,
Cancer cell-derived long pentraxin 3 (PTX3) promotes melanoma migration through a toll-like receptor 4 (TLR4)/NF-kappaB signaling pathway, Oncogene, vol.38, pp.5873-5889, 2019. ,
MITF and c-Jun antagonism interconnects melanoma dedifferentiation with pro-inflammatory cytokine responsiveness and myeloid cell recruitment, Nat. Commun, vol.6, 2015. ,
Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis, Eur. Respir. J, vol.29, pp.976-985, 2007. ,
Nintedanib in the management of idiopathic pulmonary fibrosis: Clinical trial evidence and real-world experience, Ther. Adv. Respir. Dis, vol.12, 2018. ,
Pharmacological treatment of idiopathic pulmonary fibrosis-preclinical and clinical studies of pirfenidone, nintedanib, and N-acetylcysteine, Eur. Clin. Respir. J, vol.2, 2015. ,
Use of multitarget tyrosine kinase inhibitors to attenuate platelet-derived growth factor signalling in lung disease, Eur. Respir. Rev, vol.26, 2017. ,
Change in non-small-cell lung cancer tumor size in patients treated with nintedanib plus docetaxel: Analyses from the Phase III LUME-Lung 1 study, OncoTargets Ther, vol.11, pp.4573-4582, 2018. ,
Sorafenib: A potential therapeutic drug for hepatic fibrosis and its outcomes, Biomed. Pharmacother, vol.88, pp.459-468, 2017. ,
Imatinib treatment for gastrointestinal stromal tumour (GIST), J. Cell. Mol. Med, vol.14, pp.42-50, 2010. ,
Positive effect of low-dose imatinib mesylate in a patient with nephrogenic systemic fibrosis, Acta Derm. Venereol, vol.91, pp.478-479, 2011. ,
Nilotinib (Tasigna) in the treatment of early diffuse systemic sclerosis: An open-label, pilot clinical trial, Arthritis Res. Ther, vol.17, p.213, 2015. ,
Dasatinib for chronic myelogenous leukemia improves skin symptoms of systemic sclerosis, Int. J. Hematol, vol.109, pp.718-722, 2019. ,
Intracellular tyrosine kinases as novel targets for anti-fibrotic therapy in systemic sclerosis, Rheumatology (Oxford), vol.47, pp.10-11, 2008. ,
Suppression of TGF-beta pathway by pirfenidone decreases extracellular matrix deposition in ocular fibroblasts in vitro, PLoS ONE, vol.12, 2017. ,
Effect of pirfenidone on proliferation, TGF-beta-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts, Eur. J. Pharm. Sci, vol.58, pp.13-19, 2014. ,
Inhibition of transforming growth factor beta signaling by halofuginone as a modality for pancreas fibrosis prevention, Pancreas, vol.38, pp.427-435, 2009. ,
Lysyl oxidase activity contributes to collagen stabilization during liver fibrosis progression and limits spontaneous fibrosis reversal in mice, FASEB J, vol.30, pp.1599-1609, 2016. ,
Matrix crosslinking forces tumor progression by enhancing integrin signaling, Cell, vol.139, pp.891-906, 2009. ,
The potential for LOXL2 as a target for future cancer treatment, Future Oncol, vol.7, pp.707-710, 2011. ,
Pre-clinical evaluation of small molecule LOXL2 inhibitors in breast cancer, Oncotarget, vol.8, pp.26066-26078, 2017. ,
Integrins in wound healing, fibrosis and tumor stroma: High potential targets for therapeutics and drug delivery, Adv. Drug Deliv. Rev, vol.129, pp.37-53, 2018. ,
Antifibrotic effects of focal adhesion kinase inhibitor in bleomycin-induced pulmonary fibrosis in mice, Am. J. Respir. Cell Mol. Biol, vol.49, pp.536-543, 2013. ,
Inhibition of focal adhesion kinase prevents experimental lung fibrosis and myofibroblast formation, Arthritis Rheumatol, vol.64, pp.1653-1664, 2012. ,
Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy, Nat. Med, vol.22, pp.851-860, 2016. ,
YAP/TAZ Signaling as a Molecular Link between Fibrosis and Cancer, Int. J. Mol. Sci, vol.19, 2018. ,
Yap/Taz Deletion in Gli(+) Cell-Derived Myofibroblasts Attenuates Fibrosis, J. Am. Soc. Nephrol, vol.28, pp.3278-3290, 2017. ,
PAK proteins and YAP-1 signalling downstream of integrin beta-1 in myofibroblasts promote liver fibrosis, Nat. Commun, 2016. ,
5-Aryl-1,3,4-oxadiazol-2-ylthioalkanoic Acids: A Highly Potent New Class of Inhibitors of Rho/Myocardin-Related Transcription Factor (MRTF)/Serum Response Factor (SRF)-Mediated Gene Transcription as Potential Antifibrotic Agents for Scleroderma, J. Med. Chem, vol.62, pp.4350-4369, 2019. ,
The Rho/MRTF pathway inhibitor CCG-222740 reduces stellate cell activation and modulates immune cell populations in Kras(G12D); Pdx1-Cre (KC) mice, Sci. Rep, vol.9, p.7072, 2019. ,